Recombinant Human NgR3/NgRH2 Protein

重组人NgR3/NgRH2蛋白 | 重组人网状蛋白-4受体样1蛋白

DKFZp547J144 | NgR3 | NgRH2 | NGRL2 | nogo receptor-like 2 | Nogo-66 receptor homolog 2 | Nogo-66 receptor-related protein 3 | reticulon 4 receptor-like 1 | reticulon-4 receptor-like 1 | RTN4RL1

rp188278-10μg

10μg

无动物源

≥95%(SDS-PAGE)

NgR3/NgRH2 (also known as reticulon-4 receptor-Like 1), along with the related NgR1 and NgR2, is a member of the Nogo66 receptor (NgR) family. NgR proteins are expressed primarily by neurons in the central and peripheral mammalian nervous system. NgR proteins play an essential role in mediating axon growth inhibition induced by the structurally distinct proteins Nogo, myelin associated glycoprotein (MAG), and myelin oligodendrocyte glycoprotein (OMgp). These proteins belong to the family of myelin-associated inhibitors (MAIs). NgR proteins are composed of 8 leucine-rich repeats (LRRs) flanked by N-terminal and C-terminal leucine-rich capping domains and are attached at the cell surface by a C-terminal glycosylphosphatidylinositol (GPI) anchor. Because NgR proteins have no transmembrane domain, they must be associated with membrane proteins in order to transduce cell signaling. Both NGF R/TNFRSF16 (p75) and TROY/TNFRSF19 have been identified as NgR1-associated components. Human NgR3 shares 88% and 86% amino acid sequence identity with mouse and rat NgR3 respectively. NgR1 and NgR3 serve as receptors for chondroitin sulfate proteoglycans (CSPGs). NgR3 may function as a NgR1 co-receptor for Nogo66. CSPGs and MAIs are known to stabilize neuronal structure and influence the growth and guidance of developing neurons. Therefore, NgR proteins are part of a multicomponent receptor system implicated in pathways that limit neuronal growth and increase the structural stability of synapses.

Immobilized Recombinant Human NgR3/NgRH2 Protein (rp188278) at 1.0 μg/mL can bind Recombinant NgR3 Antibody (Ab118008) with the EC50 of 3.0 ng/mL.

重组表达

45.3 kDa

C-His

52.5-66.4 kDa, under reducing conditions; 48.2-64.9 kDa, under non-reducing conditions.

HEK293 Accession #: Q86UN2 | HEK293

<1.0 EU/μg

人(Human)

1-419 aa

MLRKGCCVELLLLLVAAELPLGGGCPRDCVCYPAPMTVSCQAHNFAAIPEGIPVDSERVFLQNNRIGLLQPGHFSPAMVTLWIYSNNITYIHPSTFEGFVHLEELDLGDNRQLRTLAPETFQGLVKLHALYLYKCGLSALPAGVFGGLHSLQYLYLQDNHIEYLQDDIFVDLVNLSHLFLHGNKLWSLGPGTFRGLVNLDRLLLHENQLQWVHHKAFHDLRRLTTLFLFNNSLSELQGECLAPLGALEFLRLNGNPWDCGCRARSLWEWLQRFRGSSSAVPCVSPGLRHGQDLKLLRAEDFRNCTGPASPHQIKSHTLTTTDRAARKEHHSPHGPTRSKGHPHGPRPGHRKPGKNCTNPRNRNQISKAGAGKQAPELPDYAPDYQHKFSFDIMPTARPKRKGKCARRTPIRAPSGVQQAHHHHHH​

Yes

Yes